RxDoctor Payments Data

Michele Gocuay, MD

Internal Medicine · Houston, TXNPI 1144401027

Payments from drug & device makers

$1,379in general payments, 2019–2025

Across 73 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$138
  • Novo Nordisk$126
  • GSK$119
  • Exact Sciences$98
  • Abbott$93
  • Amgen$84
  • plus $721 from 20 others

What the payments were for

  • Food & beverage$1,379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,379 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$115,184
Medicare patients
316
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$186,690
JardianceEmpagliflozin55$52,046
MounjaroTirzepatide31$43,533
RybelsusSemaglutide32$36,694
JanuviaSitagliptin Phosphate18$29,431
FarxigaDapagliflozin Propanediol32$27,487
EliquisApixaban24$26,320
Tresiba Flextouch U-200Insulin Degludec16$19,017
Breo ElliptaFluticasone/Vilanterol20$16,979
TrulicityDulaglutide13$12,852
Repatha SureclickEvolocumab15$8,560
Tresiba Flextouch U-100Insulin Degludec12$7,380
Atorvastatin Calcium643$5,992
Mirabegron ErMirabegron11$4,824
Levothyroxine Sodium380$4,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$126$223,383176 claims
Lilly USA, LLCMounjaro, Trulicity$48$56,38544 claims
Boehringer IngelheimJardiance$48$52,04655 claims
AstraZenecaFarxiga$54$27,48732 claims
GSKBreo Ellipta$119$16,97920 claims
AbbVieSynthroid$45$3,59155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →